Sector News

Amgen to acquire biopharma firm ChemoCentryx for $3.7bn

August 7, 2022
Life sciences

Amgen has signed a definitive agreement to acquire biopharmaceutical company ChemoCentryx for $52 for each share in cash or a total enterprise cost of nearly $3.7bn.

ChemoCentryx focuses on orally administered therapeutics for the treatment of inflammatory disorders, autoimmune ailments and cancer.

For discovering, developing and marketing such treatments, the company targets the chemokine and chemoattractant systems.

With the takeover, Amgen will gain access to ChemoCentryx ’s Tavneos (avacopan), a therapy for serious autoimmune diseases.

This therapy complements Amgen ‘s expertise in inflammation and nephrology.

An orally administered selective inhibitor of complement component 5a receptor, Tavneos received approval from the US Food and Drug Administration (FDA) in October last year.

It is approved as an adjunctive therapy along with standard therapy for treating adults with severe active ANCA-associated vasculitis, particularly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Furthermore, Tavneos has received approvals in key markets, including the EU and Japan.

The company also has an oral checkpoint inhibitor for cancer and three early-stage therapy candidates that act on chemoattractant receptors in other inflammatory ailments.

The board of directors of Amgen and ChemoCentryx has granted unanimous approval for the acquisition.

Subject to necessary approvals and closing conditions, the deal is anticipated to conclude in the fourth quarter of this year.

Amgen chairman and CEO Robert Bradway said: “The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with Tavneos, a transformative, first-in-class treatment for ANCA-associated vasculitis.

“We are excited to join in the Tavneos launch and help many more patients with this serious and sometimes life-threatening disease for which there remains significant unmet medical need.”

In October last year, the company acquired all outstanding shares of clinical-stage biotechnology firm Teneobio for $2.5bn.

Source: pharmaceutical-technology.com

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.